705292-97-3

Upstream product

• 690257-96-6 (2S,3E)-4-(4-bromophenyl)-3-buten-2-ol 
• 201996-64-7 (E)-3-(4-bromophenyl)-N-methoxy-N-methylacrylamide 
• 1200-07-3 trans-4-bromocinnamic acid 
• 690257-97-7 (1S,2E)-3-(4-bromophenyl)-1-methylprop-2-en-1-yl N-(tert-butoxycarbonyl)glycinate 
• 690258-03-8 (βS)-4-bromo-N-(tert-butoxycarbonyl)-β-[(1E)-prop-1-en-1-yl]-L-phenylalanine 
• 136725-53-6 (S)-3-fluoropyrrolidine hydrochloride 
• 690257-98-8 methyl (βS)-4-bromo-N-(tert-butoxycarbonyl)-β-[(1E)-prop-1-enyl]-L-phenylalaninate 
• 136725-54-7 (3S)-3-fluoropyrrolidine 

Downstream Products

• 860779-34-6 [(E)-(1S,2S)-1-((S)-3-Fluoro-pyrrolidine-1-carbonyl)-2-(4-pyridin-3-yl-phenyl)-pent-3-enyl]-carbamic acid tert-butyl ester 
• 860779-35-7 [(E)-(1S,2S)-1-((S)-3-Fluoro-pyrrolidine-1-carbonyl)-2-(4-pyridin-4-yl-phenyl)-pent-3-enyl]-carbamic acid tert-butyl ester 
• 860779-32-4 {(E)-(1S,2S)-1-((S)-3-Fluoro-pyrrolidine-1-carbonyl)-2-[3'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-pent-3-enyl}-carbamic acid tert-butyl ester 
• 705292-98-4 (2S,3S)-3-N-(tert-butoxycarbonyl)amino-2-(4-bromophenyl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-N,N-dimethyl-4-oxobutanamide 
• 705293-00-1 tert-butyl [(1S,2S)-3-(dimethylamino)-1-{[(3S)-3-fluoropyrrolidin-1-yl]carbonyl}-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-oxopropyl]carbamate 
• 705293-01-2 tert-butyl [(1S,2S)-3-(dimethylamino)-1-{[(3S)-3-fluoropyrrolidin-1-yl]carbonyl}-2-(4-hydroxyphenyl)-3-oxopropyl]carbamate 
• 870773-56-1 (3S)-1-[(2S,3S)-3-(4-(N-butoxycarbonyl)phenyl)-2-(tert-butoxycarbonylamino)-3-(dimethylaminocarbonyl)-1-oxopropanyl]-3-difluoropyrrolidine 
• 870784-23-9 (2S,3S)-3-[(tert-butoxylcarbonyl)amino]-4-((3S)-3-fluoropyrrolidin-1-yl)-2-[4-(N-butoxycarboxylcyclohexyl)]-N,N-dimethyl-4-oxobutanamide 

Relevant academic research and scientific papers

(2S,3S)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1, 2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective α-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

A series of β-substituted biarylphenylalanine amides were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of type 2 diabetes. Optimization of the metabolic profile of early analogues led to the discovery of (2S

CYCLOHEXYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel cyclohexylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Discovery of potent and selective orally bioavailable β-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors

anti-Substituted biaryl β-methylphenylalanine derived amides have been shown to be potent DPP-IV inhibitors that suffer from suboptimal selectivity and pharmacokinetics. This letter describes the substitution of the β-methyl substituent with β-polar subst